This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment [Yahoo! Finance]
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: Yahoo! Finance
Artiva Biotherapeutics (NASDAQ: ARTV) is making waves with its potentially groundbreaking treatment since its July IPO, fueling bold analyst predictions. Based on the company's share price of around $10 as of August 27, the average Wall Street analyst price target signals an upside of over 100%. So, what does Artiva do, and why is Wall Street so bullish on the company? Artiva: Revolutionizing the science and economics of cell therapies Artiva develops medicines in the cell therapy discipline of biotherapeutics. Doctors use cell therapies to modify, replace, or destroy cells that cause diseases. Traditionally, for cell therapies to be effective, doctors need to take cells from the body of each specific patient. The scientists then multiply and modify the cells before reintroducing them into the patient's body to treat the condition. Performing this process for each patient individually can be expensive and time-consuming. Artiva is working to solve this problem. Artiva's the
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.MarketBeat
- Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- Artiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewswire
- Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of DirectorsGlobeNewswire
- Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity [Yahoo! Finance]Yahoo! Finance
ARTV
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- ARTV's page on the SEC website